On March 26, at the 5th Peptide Industry Innovation & Development Forum, the “Peptide Future” – 2025 China Peptide Drug Industry Innovation List, co‑launched by Changsha Luocheng Trading Co., Ltd. and E‑Pharm Academy, was officially released.

Supported by PharmaDu Data, the list reviews 15‑year core industrial achievements (2010‑2025). Based on the forum’s evaluation system and expert assessment, it selects benchmark enterprises across the whole industrial chain to set new standards for China’s peptide drug sector.

Centered on the theme “Peptides Power Innovation, Shaping the Future”, the forum gathered over 1,000 industry elites, leading experts and enterprise representatives. The list release stood out as the highlight. Unveiling four major lists honors outstanding firms in the peptide drug sector and showcases China’s 15‑year innovative achievements in this industry, fueling its high‑quality growth.
Four categories are set in this selection: Top Overall Strength Enterprises, Rising‑Star Potential Enterprises, Innovation Potential Enterprises, and Most Popular Enterprises, covering the whole industrial chain of peptide drug R&D, production and commercialization. Differentiated evaluation criteria are adopted for enterprises at various growth stages with distinct core competitiveness, ensuring comprehensiveness, objectivity and scientificity. Full list is as follows:
Top Overall Strength Enterprises of China’s Peptide Drug Industry
Industry leaders with integrated strengths in R&D, production and commercialization across the whole sector:

• Gan & Lee Pharmaceuticals Co., Ltd.
• Shenzhen Hybio Pharmaceutical Co., Ltd.
• Shanghai Livzon Pharmaceutical Co., Ltd.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Innovative enterprises with benchmark‑potential core products, empowered by capital and international collaboration:

• Hangzhou Sciwind Biosciences Co., Ltd.
• Pegetide Biotech (Hangzhou) Co., Ltd.
• Guangzhou Yinno Pharmaceutical Group Co., Ltd.
• Bio-Thera Solutions, Ltd.
• Suzhou Landing Biopharmaceutical Co., Ltd

Innovation Potential Enterprises of China’s Peptide Drug Industry.

Growing enterprises/institutions featuring core technological breakthroughs, robust clinical pipelines and differentiated competitive advantages:

• BrightGene Biomedical (Suzhou) Co., Ltd.
• Tongyi Therapeutics (Suzhou) Co., Ltd.
• Shaanxi Microalt Pharmaceutical Technology Co., Ltd.
• Chengdu Paide Biomedical Co., Ltd.
• Beijing QL Biopharm Co., Ltd.
• Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.
• Jiangsu Engineering Research Center for Synthetic Peptide Drug Discovery & Evaluation
• Shanghai Hepu Pharmaceutical Co., Ltd.
• Hunan Zhongsheng Quantape Biotechnology Co., Ltd.
• Tianjin Xingliantide Biotechnology Co., Ltd.

From 2010 to 2025, China’s peptide drug industry has achieved leap‑forward development, evolving from raw material supply to independent innovative drug R&D. Boasting strong targeting, high safety and moderate R&D cycles, peptide drugs have become a key track in biopharmaceutical innovation. Remarkable progress has been made in hot targets such as GLP‑1R, with multiple candidates in late‑stage clinical trials or NDA stages, alongside frequent out‑licensing deals. Domestic firms have become vital players in the global peptide industrial chain.

The listed enterprises include industry leaders with full‑chain layout and strong commercialization capabilities, emerging players focusing on technological innovation and promising clinical pipelines, as well as benchmark firms recognized for industrial breakthroughs and market reputation. They fully demonstrate the diversified innovation ecosystem of China’s peptide drug sector.

Changsha Luocheng Trading Co., Ltd. is a specialized supplier of high-purity peptides for the cosmetic, wellness, and fitness industries. Our core products include cosmetic peptides, anti-aging peptides, weight management peptides, and muscle-building peptides – serving skincare brands, supplement formulators, and health-focused companies worldwide.